Community Advisory Board

Readers Rep

Markets:

Overview

News

Currencies

International

Treasuries

Theralase Technologies Inc (TSV:TLT)

0.2300 -0.0100 (-4.17%)

Streaming Delayed Price Updated: 3:59 PM EDT, May 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Theralase Technologies Inc

< Previous 1 2 3 4 Next >

Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update

May 04, 2026

Toronto, Ontario--(Newsfile Corp. - May 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the...

Via Newsfile

Theralase(R) Reports Complete Response with X-Ray-Activated Rutherrin(R) in Muscle Invasive Bladder Cancer Preclinical Study

April 13, 2026

Toronto, Ontario--(Newsfile Corp. - April 13, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...

Via Newsfile

Theralase(R) Closes $CAN 2.66 Million Financing

April 10, 2026

Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...

Via Newsfile

Theralase(R) Discovers Further Mechanism on How Ruvidar(R) Inactivates Herpes Simplex Virus

March 17, 2026

Toronto, Ontario--(Newsfile Corp. - March 17, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...

Via Newsfile

Theralase(R) Closes $1.1 M Non-Brokered Private Placement

March 10, 2026

Toronto, Ontario--(Newsfile Corp. - March 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical...

Via Newsfile

Theralase(R) Demonstrates That X-Ray-Activated Rutherrin(R) Is Significantly More Effective than Radiation Alone in the Destruction of Muscle Invasive Bladder Cancer

March 09, 2026

Toronto, Ontario--(Newsfile Corp. - March 9, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical...

Via Newsfile

Correcting and Replacing: Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress

February 20, 2026

This Press Release identifies that Dr. Kulkarni has participated in a medical advisory position for Theralase(R) in the past.Toronto, Ontario--(Newsfile...

Via Newsfile

Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress ↗

February 17, 2026

Toronto, Ontario--(Newsfile Corp. - February 17, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a...

Via Newsfile

Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting

February 10, 2026

Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...

Via Newsfile

Theralase(R) Provides Update on Bladder Cancer Clinical Study

February 04, 2026

Toronto, Ontario--(Newsfile Corp. - February 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical...

Via Newsfile

Theralase(R) Completes Enrollment in Bladder Cancer Clinical Study

February 02, 2026

Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...

Via Newsfile

Ferring Pharmaceuticals and Theralase(R) Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer

January 12, 2026

The collaborative clinical study will evaluate ADSTILADRIN® (nadofaragene firadenovec-vncg) in combination with the investigational drug Ruvidar® (TLD-1433) in patients with...

Via Newsfile

Theralase(R) Closes $1.3 M Non-Brokered Private Placement

December 23, 2025

Toronto, Ontario--(Newsfile Corp. - December 23, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...

Via Newsfile

Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing

December 12, 2025

Toronto, Ontario--(Newsfile Corp. - December 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...

Via Newsfile

Theralase(R) Investor Conference Call Reminder

November 17, 2025

Toronto, Ontario--(Newsfile Corp. - November 17, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a...

Via Newsfile

Theralase(R) Releases 3Q2025 Financial Statements

November 10, 2025

Toronto, Ontario--(Newsfile Corp. - November 10, 2025) - Theralase® Technologies Inc. (TSXV:TLT) (OTCQB:TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical pioneering...

Via Newsfile

Theralase(R) Demonstrates Effectiveness of X-Ray-Activated Drug

November 03, 2025

Toronto, Ontario--(Newsfile Corp. - November 3, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...

Via Newsfile

Independent Research Demonstrates Ruvidar(R) Effective in the Destruction of Herpes Simplex Virus

September 24, 2025

Toronto, Ontario--(Newsfile Corp. - September 24, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical...

Via Newsfile

Topics Derivatives

Theralase(R) Extends Warrants

August 29, 2025

Toronto, Ontario--(Newsfile Corp. - August 29, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...

Via Newsfile

Theralase(R) Releases 2Q2025 Financial Statements

August 26, 2025

Toronto, Ontario--(Newsfile Corp. - August 26, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...

Via Newsfile

Theralase(R) Closes Non-Brokered Private Placement

July 28, 2025

Toronto, Ontario--(Newsfile Corp. - July 28, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...

Via Newsfile

Theralase(R) Extends Warrants

June 27, 2025

Toronto, Ontario--(Newsfile Corp. - June 27, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical...

Via Newsfile

Theralase(R) Closes Non-Brokered Private Placement

June 17, 2025

Toronto, Ontario--(Newsfile Corp. - June 17, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage...

Via Newsfile

Theralase Completes Annual General and Special Meeting

June 12, 2025

Toronto, Ontario--(Newsfile Corp. - June 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical...

Via Newsfile

Theralase Annual General Meeting

June 05, 2025

Toronto, Ontario--(Newsfile Corp. - June 5, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a...

Via Newsfile

Theralase(R) 1Q2025 Financial Statements

May 30, 2025

Toronto, Ontario--(Newsfile Corp. - May 30, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a...

Via Newsfile

CORRECTION FROM SOURCE: Theralase to Present Groundbreaking Research at ASTRO 2025

May 29, 2025

This Press Release removes references to preclinical data that has not yet been presented.Toronto, Ontario--(Newsfile Corp. - May 29, 2025)...

Via Newsfile

Theralase to Present Groundbreaking Research at ASTRO 2025

May 28, 2025

Toronto, Ontario--(Newsfile Corp. - May 28, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a...

Via Newsfile

Theralase Provides Corporate Update

May 20, 2025

Toronto, Ontario--(Newsfile Corp. - May 20, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a...

Via Newsfile

Theralase Clinical Data Presented at Canadian Bladder Cancer Forum and American Urological Association

May 05, 2025

Toronto, Ontario--(Newsfile Corp. - May 5, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a...

Via Newsfile

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

About Us

Theralase Technologies Inc (TSV:TLT)

Press Releases about Theralase Technologies Inc